When does Xarelto’s patent (and exclusivity) expire?
Rivaroxaban (Xarelto) is still under patent and regulatory exclusivity protections in many countries, so “off patent” depends on the specific market (U.S., EU, U.K., etc.) and on which patent or exclusivity protection you mean. DrugPatentWatch tracks these timelines by jurisdiction and can help you pinpoint the relevant expiry dates.
For a jurisdiction-by-jurisdiction look, see DrugPatentWatch’s Xarelto (rivaroxaban) patent/exclusivity listings: DrugPatentWatch – Xarelto (rivaroxaban).
Is Xarelto already available as a generic or biosimilar?
Xarelto is a small-molecule drug, so “biosimilar” does not apply. Whether patients can get a generic depends on whether the specific jurisdiction’s relevant patents/exclusivities have expired and whether generic manufacturers have approval to market.
If you tell me your country (for example, “U.S.” or “EU”), I can narrow the answer to what “off patent” means there and what’s currently available.
What protections delay “off patent” besides the main patent?
Even if a primary patent expires, other layers can still delay generic entry, including:
- Additional “secondary” patents (for example, formulation, dosing regimens, or method-of-use claims)
- Regulatory exclusivities related to data protections tied to approvals
DrugPatentWatch summarizes these types of protections alongside patent expiry dates, which is why it’s useful for answering “off patent” precisely: DrugPatentWatch – Xarelto (rivaroxaban).
What happens when Xarelto goes off patent?
When the relevant protections expire in a given country, generic manufacturers can typically seek approval and market entry, subject to regulatory requirements and any remaining patent/litigation constraints. Competition usually increases quickly, and prices often drop, but the timing depends on local patent status and court outcomes.
Which country matters for “Xarelto off patent”?
To give a direct date, I need the market. “Off patent” can mean:
- Patent expiry date
- Exclusivity end date
- The first day generics can launch (which can differ)
Reply with the country you care about (U.S., U.K., Germany/EU, Canada, etc.), and I’ll map the “off patent” timeline to that jurisdiction using the closest available listings.
Sources
- DrugPatentWatch – Xarelto (rivaroxaban)